Type:6 Capsules
Generic Name:Lubiprostone
Manufacturer:Julphar Bangladesh Ltd.
Price:৳90.00
Irritable Bowel Syndrome with Constipation (IBS-C), Chronic idiopathic constipation, Opioid-induced Constipation (OIC) in adults with chronic non-cancer pain
Should be taken with food.
Oral Chronic idiopathic constipation Adult: 24 mcg bid daily. Irritable Bowel Syndrome With Constipation 8 mcg twice daily. Opioid-Induced Constipation Treatment in patients with chronic noncancer pain 24 mcg bid daily. Hepatic impairment Mild: Dose adjustment not necessary Moderate (Child-Pugh B): Chronic idiopathic or opioid-induced constipation, 16 mcg PO q12hr; irritable bowel syndrome with constipation (IBS-C), no dosage adjustment required Severe (Child-Pugh C): Chronic idiopathic or opioid-induced constipation, 8 mcg PO q12hr; IBS-C, 8 mcg PO q24hr
Safety and efficacy not established
History of mechanical GI obstruction.
Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating ClC-2, which is a normal constituent of the apical membrane of the human intestine. By increasing intestinal fluid secretion, Lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic idiopathic constipation.
Safety has not been established in pregnant women. Not to be used in patients with severe diarrhoea. Lactation: Unknown whether drug is excreted in breast milk; because lubiprostone increases fluid secretion in the intestine and intestinal motility, monitor breastfeeding infants for diarrhea
>10% Nausea (29%),Headache (12%),Diarrhea (11%) 1-10% Edema (3%),Chest discomfort (2%),Peripheral edema (1-3%),Fatigue (2%),Dizziness (3%),Flatulence (4-6%),Abdominal distress (3%),Dyspepsia (2%),Xerostomia (1%),Abdominal pain (4-8%),Loose stools (3%)
